A graded challenge with adalimumab could be safe in case of a delayed allergic reaction to golimumab, after a detailed allergological evaluation and the exclusion of allergic sensitization using skin tests.
Keywords: adalimumab; anti‐TNF agent; delayed reaction to biologic agent; golimumab; hypersensitivity reaction to biological; hypersensitivity to biologic agent.
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.